Crossmark

Efficacy of orally and topically administered fluralaner (Bravecto®) for treatment of client-owned dogs with sarcoptic mange under field conditions

Published Online: 2020-10-17

Published Print: 2020-12

Authors

Chiummo, Rafael

Petersen, Ivo

Plehn, Claudia

Zschiesche, Eva

Roepke, Rainer

Thomas, Emmanuel
License Information

Text and Data Mining valid from 2020-10-17

Version of Record valid from 2020-10-17
More Information

Article History

Received: 4 August 2020

Accepted: 7 October 2020

First Online: 17 October 2020

Ethics approval and consent to participate

: The study protocol was in alignment with national and global guidelines, and owners of all dogs were fully advised of all study procedures prior to signing informed consent.

: Not applicable.

: RC, IP, CP, EZ, RR and ET are employees of MSD Animal Health.

Document is current